Stockholm’s Pixelgen Technologies secures €13.26 million to advance spatial mapping of cell-surface proteins
Pixelgen Technologies, a Stockholm-based life sciences company that claims to have developed the first high-throughput platform for mapping molecular cell architecture, has closed an oversubscribed €13.26 million ($15.5 million) Series B funding round. The round was led by new investor Flat Capital, with continued participation from existing investors Industrifonden and Navigare Ventures.…
Pixelgen Technologies, a Stockholm-based life sciences firm, has closed a €13.26 million ($15.5 million) Series B funding round led by new investor Flat Capital. Existing investors Industrifonden and Navigare Ventures also participated in the oversubscribed funding round. The additional capital will support Pixelgen's global expansion, with Flat Capital CEO Rickard El Tarzi and life sciences veteran Ramon Felciano, Ph.D., joining the company's board of directors.
CEO Simon Fredriksson stated, "This financing gives us the resources to expand globally as demand grows for our Proxiome Kit and our data analysis and visualisation software." Pixelgen's Proxiome Kit is the first high-throughput platform that enables nanoscale resolution mapping of molecular cell architecture, providing researchers with novel ways to study cell function and disease mechanisms.
The company plans to use the funding to accelerate commercialisation of its technology and expand into key markets.
Written by urgent.news from EU-Startups's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
